An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Kin Fan On, Yue Chen, Hoi Tang Ma, Jeremy P.H. Chow, and Randly Y.C. Poon

(−)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling–Mediated Angiogenesis
Xiuqiang Pu, Yaoyuan Wu, Yougen Qu, Binbin Lu, Jing Chen, Jieqiong Wang, Zhengfang Yi, Weijin Qu, and Mingyao Liu

Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Deepak Raina, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I. Shapiro, Jeffrey Supko, Surender Kharbanda, and Donald Kufe

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Slocum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura, and José Baselga

High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker α-Methylacyl Coenzyme A Racemase (AMACR/P504S)
Brice A.P. Wilson, Haofan Wang, Benjamin A. Nacev, Ronnie C. Mease, Jun O. Liu, Martin G. Pomper, and William B. Isaacs
### PRECLINICAL DEVELOPMENT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>839</td>
<td>Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol</td>
<td>Jenna L. Riffell, Reiner U. Jänicke, and Michel Roberge</td>
</tr>
<tr>
<td>850</td>
<td>A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression</td>
<td>Franziska van Zijl, Sabine Mall, Georg Machat, Christine Pirker, Robert Zeillinger, Andreas Weinhaeusel, Martin Bilban, Walter Berger, and Wolfgang Mikulits</td>
</tr>
<tr>
<td>861</td>
<td>Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family</td>
<td>Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson, Neil H. James, Sue Ashton, Anna Wainwright, Jane Kendrew, Philippa Dudley, Nicola Broadbent, Graham Spraat, Sian Taylor, Claire Barnes, Jeffrey C. Silva, Charles L. Farnsworth, Laurent Hennquin, Donald J. Ogilvie, Juliane M. Jürgensmeier, Masabumi Shibuya, Stephen R. Wedge, and Simon T. Barry</td>
</tr>
</tbody>
</table>

### ABOUT THE COVER

Migration of hepatocellular carcinoma (HCC) cells that have undergone epithelial to mesenchymal transition (EMT). The 3sp cells transdifferentiated from malignant hepatocytes in the HCC patient via EMT show a migratory potential as determined by Platypus technology that can be modulated by pharmacological interference. Migrating cells are visualized by staining with CellTracker. For details, see article by van Zijl and colleagues on page 850.